In a research report released today Roth Capital analyst Scott Henry maintained a Buy rating on Tonix Pharmaceuticals (NASDAQ:TNXP) but lowered his price …
In a research report issued today, Roth Capital analyst Scott Henry assigned a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $5.00 price …
In a research report issued today, Roth Capital analyst Scott Henry reiterated a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $40 price target, as the share …
In a research report published today, Roth Capital analyst Scott Henry maintained a Buy rating on Salix Pharmaceuticals (NASDAQ:SLXP) with a $160 price …
In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on RedHill Biopharma (NASDAQ:RDHL), with a price target of …
In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $3.50 price target, …
In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on Lannett Company (NYSE:LCI) and raised his price …
In a report published today, Roth Capital analyst Scott Henry maintained a Buy rating on Lannett Company (LCI) with a $45 price target, after the company announced that it expects …
In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on Flamel Technologies (FLML) with a $20 price target, following a meeting with Flamel management. Henry wrote, “We …
In a report published today, Roth Capital analyst Scott Henry maintained a Buy rating on shares of Catalyst Pharmaceutical (CPRX) with a $3.50 price target, following the company’s second-quarter results.
